Loading...
XASXAN1
Market cap2mUSD
Aug 29, Last price  
0.01AUD
Name

Anagenics Ltd

Chart & Performance

D1W1MN
XASX:AN1 chart
P/E
—
P/S
0.34
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
37.18%
Rev. gr., 5y
8.15%
Revenues
11m
+18.54%
0000031,418141,199542,0552,196,6131,842,8043,120,3674,496,3385,647,9307,301,6867,380,8955,816,3519,234,8749,113,41410,803,168
Net income
-7m
L+180.94%
-2,760,092-4,554,782-2,688,804-3,334,546-1,339,948-2,269,637-1,970,360-1,528,041-1,473,815-3,337,348-3,498,916-4,470,136-3,732,615-5,909,557-4,907,296-3,386,632-3,648,787-2,667,150-7,493,210
CFO
-2m
L-0.75%
-2,268,742-2,891,875-1,574,617-1,100,191-1,167,439-2,328,723-1,758,269-1,452,768-2,239,805-3,123,364-2,548,712-4,060,519-4,398,757-5,934,662-4,084,361-4,168,906-2,549,343-1,780,486-1,767,085
Earnings
Feb 25, 2025

Profile

Anagenics Limited operates as a health and beauty-tech company in Australia, New Zealand, Japan, and internationally. The company develops and sales FGF5 inhibitor hair health and hair growth products under the evolis, evolis Professional, Lexilis Hybrid, Jo-Ju RED, and Lexilis BLACK brands. It markets its products through various channels, including e-commerce, television shopping, wholesale pharmacy and salons, and cross border export markets. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.
URL
https://anagenics.com/
IPO date
Dec 09, 2005
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
10,803
18.54%
9,113
-1.32%
9,235
58.77%
Cost of revenue
16,901
10,959
12,509
Unusual Expense (Income)
NOPBT
(6,098)
(1,846)
(3,274)
NOPBT Margin
Operating Taxes
(455)
5
Tax Rate
NOPAT
(6,098)
(1,391)
(3,278)
Net income
(7,493)
180.94%
(2,667)
-26.90%
(3,649)
7.74%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,212
2,634
BB yield
-37.98%
-58.25%
Debt
Debt current
471
194
903
Long-term debt
603
920
1,282
Deferred revenue
Other long-term liabilities
9
43
122
Net debt
(550)
(2,033)
(1,100)
Cash flow
Cash from operating activities
(1,767)
(1,780)
(2,549)
CAPEX
(98)
(45)
(36)
Cash from investing activities
(198)
(1,509)
(968)
Cash from financing activities
994
2,562
73
FCF
(3,512)
(967)
(2,885)
Balance
Cash
1,624
2,567
3,285
Long term investments
580
Excess cash
1,084
2,691
2,823
Stockholders' equity
2,710
8,895
8,290
Invested Capital
2,408
6,902
7,346
ROIC
ROCE
EV
Common stock shares outstanding
398,977
265,950
211,374
Price
0.01
-52.94%
0.02
 
Market cap
3,192
-29.40%
4,521
 
EV
2,642
2,488
EBITDA
(5,482)
(1,486)
(2,893)
EV/EBITDA
Interest
66
32
70
Interest/NOPBT